Skip to content

Effects of Esketamine-Propofol versus Sufentanil-Propofol Sedation on Hypoxemia and Hypotension During Endoscopic Retrograde Cholangiopancreatography (ERCP)

Effects of Esketamine-Propofol versus Sufentanil-Propofol Sedation on Hypoxemia and Hypotension During Endoscopic Retrograde Cholangiopancreatography (ERCP)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600128665
Enrollment
Unknown
Registered
2026-07-23
Start date
2026-08-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Biliary obstruction,biliary stricture, pancreatic duct stricture

Interventions

Sufentanil group (control group):Sufentanil
Esketamine group (intervention group):Esketamine

Sponsors

Beijing Friendship Hospital ,Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients undergoing ERCP; 2. ASA physical status I–III; 3. Age >=18 years; 4. BMI 18.5–30 kg/m^2; 5. Voluntary participation with signed informed consent;

Exclusion criteria

Exclusion criteria: 1. Severe hypertension (grade 3 or above; >=180/110 mmHg); 2. Severe cardiac, pulmonary, hepatic, or renal dysfunction; 3. History of central nervous system or psychiatric disorders; 4. Difficult airway; 5. Known allergy to study drugs; 6. Patients requiring general anesthesia with endotracheal intubation, or conversion to general anesthesia with intubation intraoperatively;

Design outcomes

Primary

MeasureTime frame
Incidence of intraoperative hypoxemia;

Secondary

MeasureTime frame
Incidence of intraoperative hypotension;Sedation and procedure-related indicators;Respiratory and circulatory indicators;Perioperative adverse events;Medication and recovery indicators;

Countries

China

Contacts

Public ContactRen Da

Beijing Friendship Hospital ,Capital Medical University

lize_816@163.com+86 10 63138761

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 10, 2026